The Lujian Technology & Sichuan Innovation CDMO platform serves various partners across the medical device innovation chain. Tailored service solutions are provided to meet the differentiated needs of different customer groups.

1. Startups: Accelerators from Concept to Product

Pain Points

·Lack of funding despite having technology;

·Possess patents but no manufacturing facilities;

·Have products but lack qualifications;

·High investment and long timelines for building production lines;

·Traditional contract manufacturers lack specialized expertise.

Solutions

·Shared R&D Resources: No need to build your own laboratory or cleanroom; share platform R&D resources.

·Full Regulatory Support: Platform-led or assisted full-process support from classification and testing to registration filing, bridging the regulatory talent gap for startups.

·Technical Empowerment: Platform engineers assist in design optimization and process development, addressing engineering challenges from “lab samples” to “marketable products.”

·Turnkey Solutions: One-stop services from concept validation to obtaining registration certificates, enabling founding teams to focus on core technological innovation and market development.

· Value Creation: Save more than 70% in fixed asset investments, shorten R&D cycles by 30%, and concentrate limited funds on core technological breakthroughs.

2. Established Enterprises: Strategic Partners for Production Flexibility and Process Optimization

Pain Points

·Market demand fluctuations lead to capacity bottlenecks, and building production lines is costly with high idle risks;

·Lack of rapid prototyping capabilities for new product introductions, leading to missed market windows;

·Lack of external technical support for process optimization, limiting product competitiveness;

·A rich product portfolio but insufficient flexible production capabilities.

Solutions

·Capacity Flexibility: Serve as "flexible buffer" for company capacity, offering contract manufacturing during peak sales seasons, without the need to expand factories for short-term demand.

·Rapid New Product Introduction: Utilize CDMO capabilities to quickly complete process development and pilot production, and then decide whether to build in-house production lines after market validation.

·Process Optimization: Platform engineers assist in process improvements, cost reductions, and quality enhancements, using technological iterations to boost product competitiveness.

·Modular Flexible Manufacturing: Support multi-product, small-batch production, adapting to the extensive product matrix of large enterprises.

·Value Creation: Help companies achieve "asset-light" operations, converting fixed costs into variable costs, thus improving asset turnover rates.

3. Research Institutions: Bridging the Gap for Patent Commercialization

Pain Points

·Rich patent portfolio but lack the engineering capability to convert “papers” into “products”;

·No experience in regulatory affairs, preventing excellent patents from crossing the commercialization gap;

·Absence of concept validation, hindering the demonstration of commercial feasibility for innovative technologies.

Solutions

·Concept Validation Support: Partnering with West China Hospital, Sichuan Provincial Cancer Hospital, and the Chinese Academy of Sciences to provide concept validation services through rapid prototyping to verify technical feasibility.

·Rapid Patent Monetization: Assist in patent evaluation, technology incubation, and business matchmaking, facilitating the commercial loop from “paper → patent → product.”

·Full Technological Commercialization: Provide end-to-end services from blueprint design, animal testing, and regulatory inspection to clinical trials, bridging innovation concepts to commercial products.

·Value Creation: Help hospitals complete over a hundred patent screenings and conversions, shortening typical project cycles by 40%, significantly improving the efficiency of research results conversion and unlocking the economic and social value of “sleeping patents.”

4. Medical Institutions: Co-Creators of Products Driven by Clinical Needs

Pain Points

·Rich clinical ideas but lack engineering resources and regulatory knowledge to transform them into medical devices;

·Disconnect between clinical and engineering languages, making it hard to define products that precisely match the need;

·Multiple constraints in technology commercialization due to policies, funding, and talent, resulting in severe bottlenecks in the “last mile.”

Solutions

·Clinical Concept Validation: Deep collaboration with leading top-tier hospitals across the country to rapidly create prototypes and verify feasibility based on clinical improvement needs.

·MedTech Integration: Platform engineers work closely with clinical doctors to translate clinical language into engineering language, ensuring product definitions align with real clinical scenarios.

·Compliant Conversion Pathways: Familiar with policies related to medical institutions’ technology commercialization, assisting in completing asset evaluation, conversion pathway design, and revenue-sharing plan formulation.

·Value Creation: Through effective coordination between “clinical needs - technological innovation - product implementation,” enable fast conversion of innovative results, enhancing hospital scientific research influence and industrial contributions, and ensuring clinical ideas truly benefit patients.

5. International Enterprises: Localization Platform for the Chinese Market

Pain Points

·Complex Chinese registration regulations with long and costly import registration cycles;

·High local production requirements and lack of manufacturing bases that meet international standards;

·Unfamiliarity with market channels, making it difficult to adapt to the rapidly changing Chinese market demands.

Solutions

·International Technology Domestic Substitution: Collaborating with international organizations such as the Israel Innovation Authority and Gordian Surgical to help foreign innovative technologies achieve localized production and registration in China.

·Chinese Manufacturing Base: Leverage the platform’s FDA-standard quality system to use China as a global production base, realizing “Made in China, Sold Globally.”

·Dual Reporting Strategy: Simultaneously advancing NMPA and FDA registrations, assisting in multi-market layouts for China, the US, and Europe.

·Value Creation: Provide “turnkey” services to significantly lower market entry barriers and risks in China, accelerating the global deployment of innovative technologies and benefiting Chinese patients.